LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 18

Search options

  1. Article ; Online: Don't throw the baby out with the bath water.

    Horsley, Patrick J / Kneebone, Andrew / Eade, Thomas N / Hruby, George

    The Prostate

    2021  Volume 82, Issue 3, Page(s) 397–398

    MeSH term(s) Aged ; Data Accuracy ; Endpoint Determination ; Humans ; Male ; Neoplasm Metastasis/therapy ; Neoplasm Staging ; Patient Selection ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/radiotherapy ; Radiotherapy/methods ; Radiotherapy/trends ; Survival Analysis ; Treatment Outcome
    Language English
    Publishing date 2021-12-14
    Publishing country United States
    Document type Letter
    ZDB-ID 604707-5
    ISSN 1097-0045 ; 0270-4137
    ISSN (online) 1097-0045
    ISSN 0270-4137
    DOI 10.1002/pros.24284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1608: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Radiation oncology during COVID-19: Strategies to avoid compromised care.

    Horsley, Patrick J / Back, Michael / Lamoury, Gillian / Porter, Brian / Booth, Jeremy / Eade, Thomas N

    Asia-Pacific journal of clinical oncology

    2020  Volume 17, Issue 1, Page(s) 24–28

    Abstract: The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for ... ...

    Abstract The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for those who are hospitalized however, is high. Resources for usual cancer care will likely be limited. Decisions to alter, delay or omit treatment during this period should consider both the risk of the cancer and of COVID-19 to the patient, as well as resource constraints. There is a need for departments to adapt with goals of maintaining an uninterrupted, high quality service and of minimizing compromise to oncologic care.
    MeSH term(s) COVID-19/complications ; COVID-19/diagnostic imaging ; Humans ; Neoplasms/complications ; Neoplasms/diagnostic imaging ; Neoplasms/therapy ; Pandemics ; Radiation Oncology ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-09-07
    Publishing country Australia
    Document type Journal Article ; Review
    ZDB-ID 2187409-8
    ISSN 1743-7563 ; 1743-7555
    ISSN (online) 1743-7563
    ISSN 1743-7555
    DOI 10.1111/ajco.13456
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Prostate adenocarcinoma with mucinous features - is it PSMA avid?

    Horsley, Patrick J / Sheehan-Dare, Gemma / Mastrocostas, Katerina / Fung, Caroline / Kneebone, Andrew / Eade, Thomas N / Emmet, Louise / Lalak, Andre / Hruby, George

    Journal of medical imaging and radiation oncology

    2021  Volume 66, Issue 5, Page(s) 637–640

    Abstract: Mucinous prostate adenocarcinoma represents <0.1% of prostate cancers. To our knowledge, no previous report has described ... ...

    Abstract Mucinous prostate adenocarcinoma represents <0.1% of prostate cancers. To our knowledge, no previous report has described the
    MeSH term(s) Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/radiotherapy ; Aged, 80 and over ; Androgen Antagonists ; Edetic Acid ; Gallium Radioisotopes ; Humans ; Magnetic Resonance Imaging ; Male ; Oligopeptides ; Positron Emission Tomography Computed Tomography ; Prostate/pathology ; Prostate-Specific Antigen ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/radiotherapy
    Chemical Substances Androgen Antagonists ; Gallium Radioisotopes ; Oligopeptides ; Edetic Acid (9G34HU7RV0) ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2021-09-15
    Publishing country Australia
    Document type Case Reports ; Letter
    ZDB-ID 2389687-5
    ISSN 1754-9485 ; 1440-1673 ; 1754-9477 ; 0004-8461
    ISSN (online) 1754-9485 ; 1440-1673
    ISSN 1754-9477 ; 0004-8461
    DOI 10.1111/1754-9485.13327
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 66: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Radiation oncology during COVID-19: Strategies to avoid compromised care

    Horsley, Patrick J / Back, Michael / Lamoury, Gillian / Porter, Brian / Booth, Jeremy / Eade, Thomas N

    Asia Pac. j. clin.oncol

    Abstract: The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for ... ...

    Abstract The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for those who are hospitalized however, is high. Resources for usual cancer care will likely be limited. Decisions to alter, delay or omit treatment during this period should consider both the risk of the cancer and of COVID-19 to the patient, as well as resource constraints. There is a need for departments to adapt with goals of maintaining an uninterrupted, high quality service and of minimizing compromise to oncologic care.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #745723
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Radiation oncology during COVID‐19

    Horsley, Patrick J / Back, Michael / Lamoury, Gillian / Porter, Brian / Booth, Jeremy / Eade, Thomas N

    Asia-Pacific Journal of Clinical Oncology ; ISSN 1743-7555 1743-7563

    Strategies to avoid compromised care

    2020  

    Keywords Oncology ; General Medicine ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    DOI 10.1111/ajco.13456
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Radiation oncology during COVID?19

    Horsley, Patrick J / Back, Michael / Lamoury, Gillian / Porter, Brian / Booth, Jeremy / Eade, Thomas N

    Strategies to avoid compromised care

    2020  

    Abstract: The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for ... ...

    Abstract The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for those who are hospitalized however, is high. Resources for usual cancer care will likely be limited. Decisions to alter, delay or omit treatment during this period should consider both the risk of the cancer and of COVID-19 to the patient, as well as resource constraints. There is a need for departments to adapt with goals of maintaining an uninterrupted, high quality service and of minimizing compromise to oncologic care.
    Keywords COVID-19 ; Coronavirus ; covid19
    Language English
    Publishing country au
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Outcomes for elderly patients 75 years and older treated with curative intent radiotherapy for mucosal squamous cell carcinomas of the head and neck.

    Horsley, Patrick J / Perera, Lakmalie / Veness, Michael J / Stevens, Mark J / Eade, Thomas N / Back, Michael / Brown, Chris / Jayamanne, Dasantha T

    Head & neck

    2019  Volume 42, Issue 1, Page(s) 25–32

    Abstract: Background: Elderly patients with mucosal squamous cell carcinomas of the head and neck (mHNSCC) represent a challenging clinical dilemma.: Methods: A retrospective review was performed of patients ≥75 years, treated with curative-intent radiotherapy ...

    Abstract Background: Elderly patients with mucosal squamous cell carcinomas of the head and neck (mHNSCC) represent a challenging clinical dilemma.
    Methods: A retrospective review was performed of patients ≥75 years, treated with curative-intent radiotherapy for mHNSCC in two quaternary Sydney hospitals between 2007 and 2017.
    Results: Ninety-five patients met inclusion criteria. The median age was 79 years (75-94). Patients received radiotherapy alone (n = 24), concurrent chemoradiotherapy (n = 22), surgery and adjuvant radiotherapy (n = 45), or surgery with adjuvant chemoradiotherapy (n = 4). Median follow-up was 4.5 years, median overall survival (OS) was 3.8 years, and 2-year and 5-year OS were 56% and 43%, respectively. Eastern Cooperative Oncology Group performance status of ≥2 (P < .001) was a statistically significant predictor of reduced OS. Thirty-four patients (36%) required hospitalization, 5 (5%) did not complete radiotherapy, and 9 (9%) were feeding tube dependent beyond 6 months.
    Conclusions: Appropriately selected elderly patients can achieve durable outcomes from curative intent radiotherapy with acceptable treatment toxicity.
    MeSH term(s) Aged ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/radiotherapy ; Chemoradiotherapy ; Chemoradiotherapy, Adjuvant ; Head and Neck Neoplasms/radiotherapy ; Humans ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/radiotherapy
    Language English
    Publishing date 2019-10-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645165-2
    ISSN 1097-0347 ; 0148-6403 ; 1043-3074
    ISSN (online) 1097-0347
    ISSN 0148-6403 ; 1043-3074
    DOI 10.1002/hed.25969
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1493: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.

    Lieng, Hester / Kneebone, Andrew / Hayden, Amy J / Christie, David R H / Davis, Brian J / Eade, Thomas N / Emmett, Louise / Holt, Tanya / Hruby, George / Pryor, David / Sidhom, Mark / Skala, Marketa / Yaxley, John / Shakespeare, Thomas P

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

    2019  Volume 140, Page(s) 68–75

    Abstract: The management of node-positive prostate cancer is highly variable, with both locoregional and systemic treatment options available. With the increasing use of novel imaging techniques such as PSMA-PET and MRI, combined with the increasing use of surgery ...

    Abstract The management of node-positive prostate cancer is highly variable, with both locoregional and systemic treatment options available. With the increasing use of novel imaging techniques such as PSMA-PET and MRI, combined with the increasing use of surgery for high-risk prostate cancer, clinical and pathological regional nodal disease is being detected at a higher rate and at an earlier stage than previously. This creates a window for a potentially curative management approach. The role of radiotherapy including optimal radiation target volumes and dose, as well as the timing and duration of accompanying systemic therapy remains uncertain. At a workshop in 2017, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified variations in the management of node-positive prostate cancer identified on primary staging or on histopathology at radical prostatectomy. FROGG reviewed the literature and developed a set of evidence-based recommendations on the appropriate investigation and management of clinically and pathologically node-positive prostate cancer. These recommendations encompass imaging techniques, radiation treatment target volumes and doses, as well as the use of androgen deprivation therapy.
    MeSH term(s) Androgen Antagonists/therapeutic use ; Humans ; Lymph Nodes/pathology ; Magnetic Resonance Imaging ; Male ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/radiotherapy
    Chemical Substances Androgen Antagonists
    Language English
    Publishing date 2019-06-06
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 605646-5
    ISSN 1879-0887 ; 0167-8140
    ISSN (online) 1879-0887
    ISSN 0167-8140
    DOI 10.1016/j.radonc.2019.05.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1926: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Multileaf Collimator Tracking Improves Dose Delivery for Prostate Cancer Radiation Therapy: Results of the First Clinical Trial.

    Colvill, Emma / Booth, Jeremy T / O'Brien, Ricky T / Eade, Thomas N / Kneebone, Andrew B / Poulsen, Per R / Keall, Paul J

    International journal of radiation oncology, biology, physics

    2015  Volume 92, Issue 5, Page(s) 1141–1147

    Abstract: Purpose: To test the hypothesis that multileaf collimator (MLC) tracking improves the consistency between the planned and delivered dose compared with the dose without MLC tracking, in the setting of a prostate cancer volumetric modulated arc therapy ... ...

    Abstract Purpose: To test the hypothesis that multileaf collimator (MLC) tracking improves the consistency between the planned and delivered dose compared with the dose without MLC tracking, in the setting of a prostate cancer volumetric modulated arc therapy trial.
    Methods and materials: Multileaf collimator tracking was implemented for 15 patients in a prostate cancer radiation therapy trial; in total, 513 treatment fractions were delivered. During each treatment fraction, the prostate trajectory and treatment MLC positions were collected. These data were used as input for dose reconstruction (multiple isocenter shift method) to calculate the treated dose (with MLC tracking) and the dose that would have been delivered had MLC tracking not been applied (without MLC tracking). The percentage difference from planned for target and normal tissue dose-volume points were calculated. The hypothesis was tested for each dose-volume value via analysis of variance using the F test.
    Results: Of the 513 fractions delivered, 475 (93%) were suitable for analysis. The mean difference and standard deviation between the planned and treated MLC tracking doses and the planned and without-MLC tracking doses for all 475 fractions were, respectively, PTV D99% -0.8% ± 1.1% versus -2.1% ± 2.7%; CTV D99% -0.6% ± 0.8% versus -0.6% ± 1.1%; rectum V65% 1.6% ± 7.9% versus -1.2% ± 18%; and bladder V65% 0.5% ± 4.4% versus -0.0% ± 9.2% (P<.001 for all dose-volume results).
    Conclusion: This study shows that MLC tracking improves the consistency between the planned and delivered doses compared with the modeled doses without MLC tracking. The implications of this finding are potentially improved patient outcomes, as well as more reliable dose-volume data for radiobiological parameter determination.
    MeSH term(s) Aged ; Aged, 80 and over ; Analysis of Variance ; Cone-Beam Computed Tomography ; Dose Fractionation ; Humans ; Male ; Middle Aged ; Movement ; Organs at Risk/radiation effects ; Particle Accelerators/instrumentation ; Prospective Studies ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/radiotherapy ; Radiotherapy, Image-Guided/instrumentation ; Radiotherapy, Image-Guided/methods ; Radiotherapy, Intensity-Modulated/methods ; Rectum/radiation effects ; Urinary Bladder/radiation effects
    Language English
    Publishing date 2015-08-01
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2015.04.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1218: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.

    Lieng, Hester / Hayden, Amy J / Christie, David R H / Davis, Brian J / Eade, Thomas N / Emmett, Louise / Holt, Tanya / Hruby, George / Pryor, David / Shakespeare, Thomas P / Sidhom, Mark / Skala, Marketa / Wiltshire, Kirsty / Yaxley, John / Kneebone, Andrew

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

    2018  Volume 129, Issue 2, Page(s) 377–386

    Abstract: The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET ... ...

    Abstract The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.
    MeSH term(s) Australia ; Humans ; Kallikreins/blood ; Magnetic Resonance Imaging ; Male ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/radiotherapy ; New Zealand ; Patient Selection ; Positron-Emission Tomography ; Prostate-Specific Antigen/blood ; Prostatectomy ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Radiotherapy Dosage ; Radiotherapy, Adjuvant/methods ; Salvage Therapy/methods ; Salvage Therapy/standards
    Chemical Substances KLK3 protein, human (EC 3.4.21.-) ; Kallikreins (EC 3.4.21.-) ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2018-07-20
    Publishing country Ireland
    Document type Journal Article ; Practice Guideline
    ZDB-ID 605646-5
    ISSN 1879-0887 ; 0167-8140
    ISSN (online) 1879-0887
    ISSN 0167-8140
    DOI 10.1016/j.radonc.2018.06.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1926: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top